Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy

Abstract

Blockade of SGLT2 activity with DAPA may reduce retinal microvascular lesions in our novel DR mouse model. In conclusion, our data demonstrates the exciting future potential of SGLT1 and/or SGLT2 inhibition as a therapeutic for DR.